Squarepoint Ops LLC Increases Holdings in Ocular Therapeutix, Inc. $OCUL

Squarepoint Ops LLC boosted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 44.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,415,913 shares of the biopharmaceutical company's stock after purchasing an additional 435,156 shares during the period. Squarepoint Ops LLC owned about 0.64% of Ocular Therapeutix worth $13,904,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of OCUL. BlackRock Inc. purchased a new stake in shares of Ocular Therapeutix in the 2nd quarter worth about $190,278,000. Summer Road LLC raised its position in Ocular Therapeutix by 6.9% during the first quarter. Summer Road LLC now owns 11,879,825 shares of the biopharmaceutical company's stock worth $100,622,000 after acquiring an additional 771,270 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Ocular Therapeutix by 5.1% during the fourth quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company's stock worth $130,842,000 after acquiring an additional 527,777 shares during the last quarter. TCG Crossover Management LLC lifted its holdings in shares of Ocular Therapeutix by 15.0% in the third quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company's stock valued at $71,510,000 after purchasing an additional 798,084 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of Ocular Therapeutix by 15.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company's stock valued at $56,148,000 after purchasing an additional 620,700 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Peter Kaiser sold 3,035 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $10.77, for a total value of $32,686.95. Following the sale, the insider directly owned 264,378 shares of the company's stock, valued at $2,847,351.06. This trade represents a 1.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 3,296 shares of the firm's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $10.78, for a total value of $35,530.88. Following the completion of the sale, the insider owned 318,326 shares in the company, valued at $3,431,554.28. The trade was a 1.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 29,877 shares of company stock worth $321,827 in the last three months. 3.10% of the stock is owned by insiders.

Ocular Therapeutix Price Performance

Shares of NASDAQ:OCUL opened at $11.47 on Thursday. The company has a market cap of $2.52 billion, a PE ratio of -8.08 and a beta of 0.97. Ocular Therapeutix, Inc. has a fifty-two week low of $6.23 and a fifty-two week high of $16.44. The firm has a 50-day simple moving average of $9.84 and a 200 day simple moving average of $9.31. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The company had revenue of $13.47 million during the quarter, compared to the consensus estimate of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.Ocular Therapeutix's quarterly revenue was down .1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.39) earnings per share. On average, sell-side analysts anticipate that Ocular Therapeutix, Inc. will post -1.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on OCUL shares. Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a research report on Friday, July 17th. Zacks Research raised Ocular Therapeutix from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Robert W. Baird boosted their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday, June 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ocular Therapeutix presently has an average rating of "Moderate Buy" and an average price target of $25.75.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.